CONCOMITANT INFECTIONS WITH HIV AND HTLV-I/HTLV-II

以前的血清学研究表明，某些感染了 人类免疫缺陷病毒(HIV)也可能感染人类 T细胞嗜淋巴病毒I型(HTLV-1)和/或II型(HTLV-II)。在……里面 我们可以用629名HIV感染者的血清进行初步研究 虽然HIV-I/HTLV-II的性传播肯定会发生 静脉吸毒者(IVDA)的血清阳性率要高得多 感染人数比其他任何艾滋病高危人群都高。也可以证明布莱克 西班牙裔IVDA的血清阳性率显著高于 白人和这种血清阳性率随着年龄的增长而增加。不幸的是 血清学方法不能区分这两种病毒的感染 因为它们具有抗原性交叉反应性。这需要隔离病毒 分子分析和/或聚合酶链式反应扩增研究。用一本小说 共培养法我们成功地从5个IVDA中分离到HTLV-II 分离株的前病毒图谱表明，可能存在一些 这种病毒家族的遗传异质性。聚合酶链反应扩增方法 已经开发出对前病毒检测具有特异性和敏感性的 在外周血单核细胞中，使用这种方法我们能够 在另外11个IVDA中检测HTLV-II感染。我们希望扩大规模 在这些初步发现的基础上，提出以下研究建议。首先，我们 将我们的血清学研究扩展到一个更大的研究小组，以便 确定了更多的双重感染患者。这将是 随后进行聚合酶链式反应扩增研究，以具体鉴定HTLV 牵涉其中。将继续使用前病毒映射进行病毒隔离 研究HTLV-II家族的遗传异质性有多显著。 最后，我们计划进行临床和免疫学方面的前瞻性研究。 具有特异性病毒鉴定的双重感染静脉滴虫的特征 可能会让人们更好地了解它们在人类疾病中的作用。

Previous serological studies have shown that certain patients infected with Human Immunodeficiency Virus (HIV) may also be infected with the Human T-cell lymphotropic Virus type I (HTLV-1) and /or type II (HTLV-II). In preliminary studies using sera from 629 HIV infected patients we could show that although sexual transmission of HIV-I/HTLV-II certainly occurs intravenous drug abusers (IVDAs) had a much higher seroprevalence of infection than any other AIDS risk group. It could also be shown that Black and Hispanic IVDAs had significantly higher seropositivity rates than whites and that seropositivity increased with age. Unfortunately serological methods cannot distinguish between infection by the two viruses because of their antigenic cross-reactivity. This requires virus isolation with molecular analysis and /or PCR amplification studies. Using a novel co-cultivation method we have successfully isolated HTLV-II from five IVDAs and provirus mapping of the isolates have suggested that there may be some genetic heterogeneity in this family of viruses. PCR amplificaticn methods have been developed which are specific and sensitive for provirus detection in peripheral blood mononuclear cells and using this method we were able to detect HTLV-II infection in an additional eleven IVDAs. We wish to expand on these preliminary findings and propose the following studies. First we will extend our serological studies to a larger study group to allow the identification of a larger number of dually infected patients. This will be followed by PCR amplification studies to specifically identify the HTLV involved. Virus isolation with provirus mapping will be continued to investigate how significant genetic heterogeneity is in the HTLV-II family. Finally we plan a prospective study of the clinical and immunological features of dually infected IVDAs which with specific virus identification may allow a better understanding of their role in human disease.